The influence of lead discovery strategies on the properties of drug candidates (original) (raw)

• Carney, S. How can we avoid the productivity gap? Drug Discov. Today 10, 1011–1013 (2005).
  Article PubMed Google Scholar
• Goodnow, R. A. & Gillespie, P. in Progress in Medicinal Chemistry Vol. 45 Ch. 1 (eds King, F. D. & Lawton, G.) 1–61 (Elsevier, Amsterdam, 2006).
  Google Scholar
• Keseru, G. M. & Makara, G. M. Hit discovery and hit-to-lead approaches. Drug Discov. Today 11, 741–748 (2006).
  Article PubMed Google Scholar
• Davis, A. M., Keeling, D. J., Steele, J., Tomkinson, N. P. & Tinker A. C. Components of successful lead generation. Curr. Top. Med. Chem. 5, 421–439 (2005).
  Article CAS PubMed Google Scholar
• Deprez, B. & Deprez-Poulain R. Trends in hit-to-lead: an update. Front. Med. Chem. 3, 653–673 (2006).
  Google Scholar
• CMR International. Drug Discovery Performance Metrics Programme. CMR International web site [online], (2004).
• Edwards, R. A., Zhang, K. & Firth, L. Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development. Drug Discov. World 67–71 (2002).
• CMR International. Drug Discovery Performance Metrics Programme, CMR International. CMR International web site [online], (2005).
• Proudfoot, J. R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 12, 1647–1650 (2002).
  Article CAS PubMed Google Scholar
• Hann, M. M., Leach, A. R. & Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856–864 (2001). Based on the property analysis of a large set of initial and optimized leads, the authors demonstrated for the first time that less complex molecules are more likely to become hits, albeit weaker binders.
  Article CAS PubMed Google Scholar
• Hann, M. M. & Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8, 255–263 (2004).
  Article CAS PubMed Google Scholar
• Lipinski, C. A. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
  Article CAS Google Scholar
• Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds J. Med. Chem. 49, 2969–2978 (2006).
  Article CAS PubMed Google Scholar
• Leeson, P. D. & Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Rev. Drug Discov. 6, 881–890 (2007). This paper reports that current medicinal chemistry produces compounds with molecular mass and cLogP higher than that of oral drugs and development compounds, emphasizing the importance of lipophilicity.
  Article CAS Google Scholar
• Fox, S. et al. High throughput screening: update on practices and success. J. Biomol. Screen. 11, 864–869 (2006).
  Article PubMed Google Scholar
• Fox, S., Farr-Jones, S., Sopchak, L., Boggs, A. & Comley, J. High throughput screening: searching for higher productivity. J. Biomol. Screen. 9, 354–358 (2004).
  Article CAS PubMed Google Scholar
• Parker, C. N. & Bajorath, J. Towards unified compound screening strategies: a critical evaluation of error sources in experimental and virtual high-throughput screening. QSAR Comb. Sci. 25, 1153–1161 (2006).
  Article CAS Google Scholar
• Macarron, R. Critical review of the role of HTS in drug discovery. Drug Discov. Today 11, 277–279 (2006). An analysis of transformations in HTS practices throughout the years with respect to targets, compounds and screening platforms.
  Article PubMed Google Scholar
• Harper, G., Pickett, S. D. & Green, D. V. S. Design of a compound screening collection for use in high throughput screening. Comb. Chem. High Throughput Screen. 7, 63–70 (2004).
  Article CAS PubMed Google Scholar
• Fox, S., Farr-Jones, S. & Yund, M. A. High throughput screening for drug discovery: continually transitioning into new technology. J. Biomol. Screen. 4, 183–186 (1999).
  Article CAS PubMed Google Scholar
• Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA 31, 11473–11478 (2006).
  Article Google Scholar
• Crisman, T. J. et al. “Plate Cherry Picking”: a novel semi-sequential screening paradigm for cheaper, faster, information-rich compound selection. J. Biomol. Screen. 12, 320–327 (2007).
  Article CAS PubMed Google Scholar
• Di, L. & Kerns, E. H. Biological assay challenges from compound solubility: strategies for bioassay optimization. Drug Discov. Today 11, 447–451 (2006).
  Article Google Scholar
• Andrews, P. R., Craik D. J. & Martin, J. L. Functional group contributions to drug–receptor interactions. J. Med. Chem. 27, 1648–1657 (1984).
  Article CAS PubMed Google Scholar
• Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615–2623 (2002).
  Article CAS PubMed Google Scholar
• Congreve, M., Carr, R., Murray, C. & Jhoti, H. A 'Rule of Three' for fragment-based lead discovery? Drug Discov. Today 8, 876–877 (2003).
  Article PubMed Google Scholar
• Hopkins, A. L., Groom, C. R. & Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9, 430–431 (2004). An introduction to the principle of ligand efficiency as a measure of the binding energy per non-hydrogen atom — a useful parameter in the selection and optimization of leads.
  Article PubMed Google Scholar
• Makara, G. M. & Athanasopoulos, J. Improving success rates for lead generation using affinity binding technologies. Curr. Opin. Biotechnol. 16, 666–673 (2005).
  CAS PubMed PubMed Central Google Scholar
• Golebiowski, A., Klopfenstein, S. R. & Portlockz D. E. Lead compounds discovered from libraries: part 2. Curr. Opin. Chem. Biol. 7, 308–325 (2003).
  Article CAS PubMed Google Scholar
• Rees, D. C., Congreve, M., Murray, C. W. & Carr, R. Fragment-based lead discovery. Nature Rev. Drug Discov. 3, 660–672 (2004).
  Article CAS Google Scholar
• Alex, A. A. & Flocco, M. M. Fragment-based drug discovery: what has it achieved so far? Curr. Top. Med. Chem. 7, 1544–1567 (2007).
  Article CAS PubMed Google Scholar
• Harvey, A. L. Natural products as a screening resource. Curr. Opin. Chem. Biol. 11, 480–484 (2007).
  Article CAS PubMed Google Scholar
• McInnes, C. Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 11, 494–502 (2007).
  Article CAS PubMed Google Scholar
• Wyss, D. F., McCoy, M. A. & Senior, M. M. NMR-based approaches for lead discovery. Curr. Opin. Drug Discov. Dev. 5, 630–647 (2002).
  CAS Google Scholar
• Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235–249 (2000).
  Article CAS PubMed Google Scholar
• Oprea, T. I., Davis, A. M., Teague, S. J. & Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41, 1308–1315 (2001).
  Article CAS PubMed Google Scholar
• Oprea, T. I. et al. Lead-like, drug-like or “pub-like”: how different are they? J. Comp. Aided Mol. Des. 21, 113–119 (2007).
  Article CAS Google Scholar
• Fobare, W. F. et al. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg. Med. Chem. Lett. 17, 5353–5356 (2007).
  Article CAS PubMed Google Scholar
• Coburn, C. A. et al. Identification of a small molecule nonpeptide active site β-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J. Med. Chem. 47, 6117–6119 (2004).
  Article CAS PubMed Google Scholar
• Durham T. B. & Shepherd, T. A. Progress toward the discovery and development of efficacious BACE inhibitors. Curr. Opin. Drug Discov. Dev. 9, 776–791 (2006).
  CAS Google Scholar
• Congreve, M. et al. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J. Med. Chem. 50, 1124–1132 (2007).
  Article CAS PubMed Google Scholar
• Edwards, P. D. et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J. Med. Chem. 50, 5912–5925 (2007).
  Article CAS PubMed Google Scholar
• Kuglstatter, A. et al. Tyramine fragment binding to BACE-1 Bioorg. Med. Chem. Lett. 18, 1304–1307 (2008).
  Article CAS PubMed Google Scholar
• Reynolds, C. H., Tounge, B. A. & Bembenek, S. D. Ligand binding efficiency: trends, physical basis, and implications J. Med. Chem. 51, 2432–2438 (2008).
  Article CAS PubMed Google Scholar
• Congreve, M., Chessari, G., Tisi, D. & Woodhead, A. J. Recent developments in fragment-based drug discovery. J. Med. Chem. 51, 3661–3680 (2008). A recent review that highlights the trends in fragment screening, screening libraries and fragment optimization strategies.
  Article CAS PubMed Google Scholar